GlassScriptPhysician profile
April A Erwin
NPI 1194976670
$263,473.07
in general payments reported to CMS, 2019-2025
61 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $18K · 2021: $6,342 · 2022: $10K · 2023: $50K · 2024: $42K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Food and Beverage: $14K · Travel and Lodging: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,650 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $96,106.06 |
| Food and Beverage | $13,732.90 |
| Travel and Lodging | $10,189.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,650.00 |
| Education | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49,773.73 | 2019-2025 | Kesimpta |
| Emd Serono, INC. | $44,820.99 | 2019-2025 | Mavenclad, Evobrutinib, Mavenclad |
| Celgene Corporation | $41,364.82 | 2019-2025 | Zeposia |
| Genzyme Corporation | $41,339.16 | 2019-2025 | |
| Biogen, INC. | $27,338.93 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Genentech USA, INC. | $27,322.57 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $20,086.60 | 2023-2025 | Briumvi |
| Abbvie INC. | $2,263.43 | 2019-2025 | |
| Ucb, INC. | $774.61 | 2019-2025 | Rystiggo, Zilbrysq, Fintepla |
| Amgen INC. | $697.75 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $649.63 | 2019-2022 | |
| Allergan, INC. | $581.39 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $399.27 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $398.00 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $337.56 | 2019-2024 | Ultomiris, Soliris |
Show all 60 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Erwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.